This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Apr 17, 2020
by Zacks Equity Research
Companies in the news are: TSM, BK, LOVE, VNDA
Vanda Begins Enrollment in Study for Severe Coronavirus Infection
by Zacks Equity Research
Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.
7 Stocks With Low Price-to-Sales Ratio for a Solid Portfolio
by Zacks Equity Research
A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Value Stocks to Buy for November 14th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 14th
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study
by Zacks Equity Research
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder.
Why Vanda (VNDA) Might be Well Poised for a Surge
by Zacks Equity Research
Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Vanda Pharmaceuticals (VNDA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 800.00% and 7.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vanda Pharmaceuticals (VNDA) Q1 Earnings Top Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 500.00% and -7.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vanda Pharmaceuticals (VNDA) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and 3.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Vanda (VNDA) Q4 Earnings: What's in Store for the Stock
by Zacks Equity Research
On Vanda's (VNDA) fourth-quarter 2018 conference call, investor focus will be on the sales figure of its two marketed drugs, Hetlioz and Fanapt.
Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
by Zacks Equity Research
Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.
Zacks.com featured highlights include: Inseego, Meet, Vanda, Crocs and Bluerock Residential
by Zacks Equity Research
Zacks.com featured highlights include: Inseego, Meet, Vanda, Crocs and Bluerock Residential
5 Stocks With Recent Price Strength Despite Volatile Market
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
by Zacks Equity Research
ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.
Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect
by Zacks Equity Research
Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.
Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan
by Zacks Equity Research
Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.
Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.